Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
Authors
Keywords
-
Journal
Vaccines
Volume 9, Issue 12, Pages 1470
Publisher
MDPI AG
Online
2021-12-13
DOI
10.3390/vaccines9121470
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis
- (2021) Maria Pia Sormani et al. ANNALS OF NEUROLOGY
- Primary prevention of COVID‐19: Advocacy for vaccination from a neurological perspective
- (2021) Johann Sellner et al. EUROPEAN JOURNAL OF NEUROLOGY
- Public health challenges and opportunities after COVID-19
- (2021) Pier Luigi Sacco et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses
- (2021) Ilies Benotmane et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antibody titers and protection against a SARS-CoV-2 infection
- (2021) Chloé Dimeglio et al. JOURNAL OF INFECTION
- Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
- (2021) Sokratis A. Apostolidis et al. NATURE MEDICINE
- Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis
- (2021) Giulio Disanto et al. JAMA Neurology
- Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab
- (2021) Livnat Brill et al. JAMA Neurology
- DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France
- (2021) Maria Pia Sormani et al. Annals of Clinical and Translational Neurology
- Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies
- (2021) Maria Pia Sormani et al. EBioMedicine
- SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
- (2021) Daryl Geers et al. Science Immunology
- Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
- (2021) Leoni Rolfes et al. Neurology-Neuroimmunology & Neuroinflammation
- Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies
- (2021) Ahya Ali et al. VACCINE
- Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis
- (2021) Frederik Novak et al. Multiple Sclerosis and Related Disorders
- SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy
- (2021) Eva C. Schulte et al. EBioMedicine
- T cells as the hoped-for savior for SARS-CoV-2 vaccination during CD20-depleting antibody therapy?
- (2021) Gabriel Bsteh et al. EBioMedicine
- The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2
- (2021) Tzu-Chuan Ho et al. Vaccines
- Worldwide Vaccination Willingness for COVID-19: A Systematic Review and Meta-Analysis
- (2021) Kimberly R. Nehal et al. Vaccines
- Infections in patients diagnosed with multiple sclerosis: A multi-database study
- (2020) R. Persson et al. Multiple Sclerosis and Related Disorders
- B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran
- (2020) Farinaz Safavi et al. Multiple Sclerosis and Related Disorders
- Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
- (2020) Takuya Sekine et al. CELL
- Infections in patients with multiple sclerosis: A national cohort study in Sweden
- (2020) Anna Castelo-Branco et al. Multiple Sclerosis and Related Disorders
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies
- (2020) Elahe Seyed Hosseini et al. VIROLOGY
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
- (2019) Gustavo Luna et al. JAMA Neurology
- Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation
- (2015) Andrew J. Steelman Frontiers in Immunology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started